

Serogroup B Meningococcal (MenB)[®]

Age Indications and schedule for MenB Vaccines

- Trumenba[™] (MenB-FHbp) for persons aged 10 years & older
 - 3 dose series at 0, 2, 6 months
- Bexsero[®] (MenB-4C) for persons age 10 years & older
 - 2 dose series at 0, ≥1 month after 1st dose

***Both MenB vaccines are FDA-licensed for people 10 through 25 years of age**

Indications for Use:

Routine Use:

Vaccinate persons aged 10 years and older who are at increased risk for meningococcal disease:

- Anatomic or functional asplenia, including sickle cell disease
- Persistent complement component deficiencies
 - Including inherited or chronic deficiencies in C3, C5-C9, properdin, factor H, factor D or taking eculizumab [Soliris[®]]
- Microbiologists routinely exposed to isolates of *Neisseria meningitidis*
- Exposure during a community outbreak attributable to serogroup B

Consider use:


- Based on provider clinical decision, persons aged 16 through 23 years without high risk conditions may receive either vaccine for short-term protection against most strains of serogroup B disease¹
 - Preferred age is 16 through 18 years

Vaccine Administration

- Intramuscular (IM) injection in the deltoid muscle of the arm
 - 1-1.5 inch, 22-25 gauge needle
- Use professional judgment in selecting needle length
- Can be given simultaneously with other vaccines, including MCV4
- The same MenB vaccine brand must be used for all doses to complete the series²

Storage and Handling

- Store in the refrigerator between 35°-46° F (2°-8° C); Do NOT freeze
- Keep in the original box
 - Bexsero[®] and Trumenba[™] supplied as 0.5mL single-dose pre-filled syringe
 - Shake prefilled syringes well before use
 - Protect Bexsero[®] from light
 - Lay Trumenba[™] syringes flat on shelf to minimize the re-dispersion time



Contraindications

- An anaphylactic (severe allergic) reaction to a prior dose, any component of MenB vaccines, or any severe allergy to latex

Precautions

- Moderate to severe acute illness
- Bexsero[®] pre-filled syringes contain natural rubber latex in caps; may cause allergic reactions in latex sensitive individuals

Further Points

- Children less than age 10 years are not recommended to receive either vaccine, regardless of risk conditions
- Unlike Meningococcal Conjugate Vaccines (MCV4), MenB vaccines are not routinely recommended for adolescents aged 10 through 15 years without a risk condition, first year college students living in residence halls, military recruits and international travelers
- There is no preference for the use of one brand of MenB over the other
- MenB vaccine should be deferred during pregnancy and should only be used if clearly needed
- More than half of the people who get serogroup B meningococcal vaccine have mild problems following vaccination. These reactions can last up to 3 to 7 days, and include (soreness, redness, or swelling at administration site, tiredness or fatigue, headache, muscle or joint pain, fever or chills, nausea or diarrhea)
- People sometimes faint after a medical procedure, including vaccination. Sitting or lying down for about 15 minutes can help prevent fainting, and injuries caused by a fall
- MenB vaccine is approved for use in persons aged 10 through 25 years; however, because there is no theoretical difference in safety for persons aged >25 years compared to those aged 10 through 25 years, ACIP supported routine use of MenB vaccines in persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease. These recommendations do not apply to children aged <10 years. This would be considered off-label use for those > 25 years.
- Q&As regarding the use of both MCV4 and MenB in adolescents are available on the CDC website at www.cdc.gov/vaccines/vpd-vac/mening/faqs-hcp-adolescent-vaccine.html
- Serogroup B Meningococcal Vaccine Information Statement (VIS), can be found at <http://www.immunize.org/vis/>
- The new MenB recommendations are classified as Category B, meaning the recommendations allow for individual clinical decision making; Category B classification enables coverage by the Vaccines For Children program and most insurance plans

Resources:

¹Advisory Committee on Immunization Practices (ACIP) designates vaccine recommendations as either category A or category B. Category A recommendations are made for all persons in an age or risk factor group. Category B recommendations are made for individual clinical decision making. Category A & B recommendations are covered under the VFC program and under the Affordable Care Act (ACA).

² If different MenB products were administered for any of the doses, proceed with the next scheduled dose of the selected product with a minimum of 1 month since the last dose of either product, further information can be found at: <http://www.cdc.gov/vaccines/vpd-vac/mening/gaqs-hcp-adolescent-vaccine.html>.

"Use of Serogroup B Meningococcal Vaccine in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015," available at www.cdc.gov/mmwr/pdf/wk/mm6441.pdf, pages 1171-6.